|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:adverseEvents
|
gptkb:ARIA-E
gptkb:ARIA-H
infusion-related reactions
|
|
gptkbp:ageRange
|
50-90 years
|
|
gptkbp:conditionStudied
|
gptkb:Alzheimer's_disease
|
|
gptkbp:cosponsor
|
gptkb:Biogen
|
|
gptkbp:duration
|
18 months
|
|
gptkbp:enrollment
|
1795
|
|
gptkbp:foundIn
|
lecanemab slowed cognitive decline in early Alzheimer's disease
|
|
gptkbp:fullName
|
Clarity Alzheimer’s Disease Study
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
CLARITY-AD
|
|
gptkbp:includes
|
amyloid positivity
early Alzheimer's disease
|
|
gptkbp:intervention
|
gptkb:lecanemab
|
|
gptkbp:location
|
multinational
|
|
gptkbp:number
|
gptkb:NCT03887455
|
|
gptkbp:period
|
Phase 3
|
|
gptkbp:primaryCompletionDate
|
March 2022
|
|
gptkbp:principalInvestigator
|
Christopher van Dyck
|
|
gptkbp:publishedResults
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:publishedResultsDate
|
November 2022
|
|
gptkbp:result
|
change in CDR-SB score
|
|
gptkbp:sponsor
|
gptkb:Eisai
|
|
gptkbp:startDate
|
March 2019
|
|
gptkbp:studyType
|
double-blind
placebo-controlled
randomized
|
|
gptkbp:website
|
https://clinicaltrials.gov/ct2/show/NCT03887455
|
|
gptkbp:bfsParent
|
gptkb:lecanemab
|
|
gptkbp:bfsLayer
|
7
|